Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment and diagnosis of cancer. The company is pursuing multiple company and investigator-sponsored clinical programs with its lead immunotherapy candidate bavituximab including the SUNRISE Phase III trial in patients with second-line non-small cell lung cancer. Other indications include front-line non-small cell lung, liver, breast and rectal cancers as well as melanoma. The company is also investigating an imaging agent that represents a potential new approach to imaging cancer. Peregrine has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ( which provides development and biomanufacturing services for both Peregrine and outside customers.
Tustin, US
211 (est)

Peregrine Pharmaceuticals Locations

Tustin, US

Peregrine Pharmaceuticals Metrics

Peregrine Pharmaceuticals Summary

Founding Date


Market capitalization

$86.6 M

Closing share price


Peregrine Pharmaceuticals Market Value History

Peregrine Pharmaceuticals News

Peregrine Pharmaceuticals Company Life